Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

http://www.wikidata.org/entity/Q35486482

about

Cholinergic imaging in dementia spectrum disorders Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.Dysfunctional Presynaptic M2 Receptors in the Presence of Chronically High Acetylcholine Levels: Data from the PRiMA Knockout Mouse.Biomarkers in translational research of Alzheimer's disease Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.The effect of APOE ε4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging.Update on the pharmacological treatment of Alzheimer's disease Use of a novel radiometric method to assess the inhibitory effect of donepezil on acetylcholinesterase activity in minimally diluted tissue samples Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction?Biological markers for early detection and pharmacological treatment of Alzheimer's disease.Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment Donepezil: a review.Donepezil: an update.Physical activity and cognition in Alzheimer's disease: relationship to vascular risk factors, executive functions and gait.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report.Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study.Positron emission tomography imaging in dementia.History of falls in Parkinson disease is associated with reduced cholinergic activity Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease.Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.PET probes for imaging brain acetylcholinesterase.Parkinson's Disease: What role do pedunculopontine nucleus cholinergic neurons play?Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action.Alterations of acetylcholinesterase activity after traumatic brain injury in rats.Central nervous system effects of haloperidol on THC in healthy male volunteers.Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with (11)C-SA4503 and microPET.Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.Asiatic acid prevents the quinolinic acid-induced oxidative stress and cognitive impairment.Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.Comparative behavioral and neurochemical analysis of phenytoin and valproate treatment on epilepsy induced learning and memory deficit: Search for add on therapy.Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia.Function of Plectranthus barbatus herbal tea as neuronal acetylcholinesterase inhibitor.

P2860

Q26764933-FC9984B5-7E94-40CE-A8F3-488DB895B831 Q28067006-E9D42B42-6A3B-4BE0-96A8-702A067706DD Q30244035-3906186A-30D1-4AB7-9BCF-0D675A4A46FD Q31011918-6E030D45-1CA8-4956-8CFA-2001D16F6A31 Q33556189-39111F58-E5BE-4CCB-990C-8739CFDE5531 Q33586027-0D2F4649-A4D9-4307-8D37-C89BB9423C17 Q33624389-65D4CD3A-C6B1-4A09-853D-E09F5824E08F Q33836947-C69FC2A4-7C8A-49EC-A404-541BEB12F33B Q34078785-585CF5E7-EA9A-44EF-8707-8D6B34C4E2D3 Q34746698-83157C37-6130-4F18-8D6E-89495A06F00F Q34965949-29AB5305-67C5-4999-B469-DEE557CB1DD8 Q35064960-E3E789E9-A13A-4EE2-B650-4EA845056650 Q35237100-3D3E630E-20C0-46E3-A655-EFA407FA0BBC Q35781558-29F61C89-7F88-451E-932A-EAD5C217DD04 Q35882869-E03A479F-CB86-47A2-A070-EC979054232E Q36544994-E55AA5BD-3F09-4235-9E4D-136FDCB9A2D9 Q36808057-BDF9FC77-D1B7-45E8-9B6D-9C31967FF887 Q36861445-3A439A10-231F-4C28-A6F4-C4388C0392B4 Q37070395-245D1AB7-EC0E-4589-B089-A5074275DDBC Q37109750-B1AE3197-ACB5-475E-943D-048A106B289A Q37138478-F4812C3E-7AE6-4369-8C31-4892A7D83867 Q37150643-E5455F72-61A8-43D0-8CC6-C99C5B25A5B2 Q37459699-A353B9B4-5070-46FC-A61D-F02F6E4E0681 Q37511433-88F293CC-EF61-4CFA-ADB9-BC979A4ED7BD Q37610784-A3DD63E4-9FAD-442B-B3D5-4FCDE2D015FE Q37639158-42757102-579A-4C6C-93FE-F94292D5D459 Q38132755-C75821D8-0520-400F-8E3F-C166AC341B85 Q38150708-3EE6F8DB-618A-4574-B941-86425CE5CAD0 Q38166972-0910C015-D047-4B1F-B1C7-F063EB3C167D Q38606300-11ED2624-2062-414E-9A0C-D08E14E5BD81 Q41975639-C86F73E0-BF85-46D7-AAA6-BADC27A7158E Q42519276-93613A37-D25D-4A7B-BBAD-46AB4E417BC3 Q43168358-C0FE99A8-3BC0-45E0-8701-741D311CF74E Q45663984-27609BD0-5601-46D6-BBFE-05CB28300316 Q47624462-544377F0-D29C-4421-8426-AB8F7B1BD98D Q47686054-018517E5-A70D-4697-A543-E6EF93E6CD2E Q47878674-3E3A941E-F112-44B5-BE0F-57A71727E41A Q48364388-467F4450-7C7C-4C9F-B8D2-7518541974E1 Q48428964-0C990472-A8BE-4FD2-A5C3-A4137B36912C Q49022359-0DC4732A-AC5C-443F-84F0-05EA4589C4FF

P2860

Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

http://www.wikidata.org/entity/Q35486482

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Degree of inhibition of cortic ...... atment in Alzheimer's disease.

@ast

Degree of inhibition of cortic ...... atment in Alzheimer's disease.

@en

type

label

Degree of inhibition of cortic ...... atment in Alzheimer's disease.

@ast

Degree of inhibition of cortic ...... atment in Alzheimer's disease.

@en

prefLabel

Degree of inhibition of cortic ...... atment in Alzheimer's disease.

@ast

Degree of inhibition of cortic ...... atment in Alzheimer's disease.

@en

P1433

Q35486482-777EADA1-18F6-486D-9719-CC154B1A954C

P1476

Q35486482-853660C6-12C8-4B02-AAFF-29DCA469264B

P2093

Q35486482-0520EE32-D33E-4B61-BE80-D1612FD7A85A

Q35486482-0FFA08BB-A11A-4AD8-88C0-844E5DCE1383

Q35486482-20D16934-0660-494C-A667-0A8305FF569F

Q35486482-2C8D4278-A01E-4A02-AD30-86A24406BF35

Q35486482-5C9F111F-A05D-4827-AB42-B017CDDB7FDB

Q35486482-9F4645E9-D441-42CE-A98C-1E9D142CBF2C

Q35486482-A328149E-E8DD-43C6-B32D-D561355B465F

Q35486482-B004F9BE-0188-4CAB-B0C1-0F129A57F500

Q35486482-BBCD792A-1FF7-4E32-AB2C-43D12586D37D

Q35486482-C16C4946-1CEA-476E-8134-2767AD071808

P2860

Q35486482-004ED86E-C4F6-4CB5-BD59-40C103645AF3

Q35486482-0668644D-D843-4313-B6F8-3E163F7C1C52

Q35486482-0DF1D8E2-3D37-4683-82DA-7B1A7EE764AF

Q35486482-166AB27F-74F0-438E-983B-3F226B773A46

Q35486482-1C99ED02-A0E3-464A-960B-C3B0D3D0B51F

Q35486482-27A2DF4B-75AC-4C3B-803C-BA431C4EA176

Q35486482-33BC8B67-B0CA-4509-957A-F8817CA9F584

Q35486482-4534A53A-5D68-4607-B0A4-7C1BA5A93C4F

Q35486482-532FD576-2FF1-466F-BA23-B6C5A8ED55E6

Q35486482-55FE882A-0EF7-4EC2-A897-5DB5987392E8

P304

Q35486482-4F4D5929-3F8E-441D-811F-2A2DDA54BA61

P31

Q35486482-9DEDBB29-BC55-436A-B248-ED9ECB0A564D

P356

Q35486482-7D16B20B-8E7E-4BE9-8B96-EA5D7F4EF7A9

P407

Q35486482-2C7D8816-ACD2-4AAD-982F-F74D98FE3FF6

P433

Q35486482-498B0A25-23BF-4FFD-9A86-A663DE9888DD

P478

Q35486482-67D14A14-4842-487D-8976-73471691F365

P50

Q35486482-DC27B1DD-44AE-4CF4-885E-3FEE625C9359

P577

Q35486482-08B99F1C-3598-417F-9733-279EDBEE7091

P5875

Q35486482-10BCC985-437D-47D9-AF49-540830884DF5

P698

Q35486482-254B6DC2-83EE-4A90-B0FC-216144624EAD

P921

Q35486482-420CF800-E834-43FF-9409-F19D5AF16CA4

P932

Q35486482-804D6A09-63C1-4BA9-900A-F2075E96E9BD

P356

JNNP.2004.038729

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Degree of inhibition of cortic ...... eatment in Alzheimer's disease

@en

P2093

B J Lopresti

http://www.w3.org/2001/XMLSchema#string

C A Mathis

http://www.w3.org/2001/XMLSchema#string

C C Meltzer

http://www.w3.org/2001/XMLSchema#string

D I Kaufer

http://www.w3.org/2001/XMLSchema#string

G Constantine

http://www.w3.org/2001/XMLSchema#string

J G Davis

http://www.w3.org/2001/XMLSchema#string

L S Ivanco

http://www.w3.org/2001/XMLSchema#string

N I Bohnen

http://www.w3.org/2001/XMLSchema#string

R A Koeppe

http://www.w3.org/2001/XMLSchema#string

R Hendrickson

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain

Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.

Cholinesterase inhibitors: A new class of psychotropic compounds.

In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease.

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Alzheimer disease, attention, and the cholinergic system.

Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB.

Cholinergic deficiency and frontal dysfunction in Parkinson's disease.

P304

315-319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.2004.038729

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Steven T Dekosky

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8015858

http://www.w3.org/2001/XMLSchema#string

P698

15716518

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1739536

http://www.w3.org/2001/XMLSchema#string